CAM
VTGN icon

ClariVest Asset Management’s VistaGen Therapeutics VTGN Stock Holding History

ClariVest Asset Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,423
Closed -$314K – 787
2022
Q1 		$314K Sell
8,423
-1,187
-12% -$51.7K 0.01% 437
2021
Q4 		$563K Sell
9,610
-160
-2% -$10.4K 0.02% 419
2021
Q3 		$804K Sell
9,770
-53
-0.5% -$4.61K 0.03% 357
2021
Q2 		$929K Buy
+9,823
New +$728K 0.03% 305

Other funds holding VTGN

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClariVest Asset Management's VTGN Position: Q2 2022 in Review

ClariVest Asset Management sold out of VistaGen Therapeutics (VTGN) in Q2 2022, closing a stake of 8,423 shares — an estimated $314K sold.

ClariVest Asset Management first reported a position in VTGN in Q2 2021 and held it in 4 quarters. The position peaked at $929K in Q2 2021. 112 funds tracked by Wall St. Rank hold VTGN as of Q2 2022.

  • ClariVest Asset Management reported no remaining VistaGen Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ClariVest Asset Management sold 8,423 VistaGen Therapeutics shares in Q2 2022, an estimated $314K.
  • ClariVest Asset Management first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 4 quarters.
  • ClariVest Asset Management's VistaGen Therapeutics position peaked at $929K in Q2 2021.
  • 112 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2022.

Based on ClariVest Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.